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We investigated the role of two MAP kinases, ERK2
and p38, in platelet adhesion and spreading over colla-
gen matrix in static and blood flow conditions. P38 was
involved in collagen-induced platelet adhesion and
spreading in static adhesion conditions, whereas ERK2
was not. In blood flow conditions, with shear rates of 300
or 1500 s1, ERK2 and p38 displayed differential involve-
ment in platelet adhesion, depending on the presence or
absence of the von Willebrand factor (vWF). Low colla-
gen coverage densities (0.04 g/cm2) did not support
vWF binding. During perfusions over this surface, plate-
let adhesion was not affected by the inhibition of ERK2
phosphorylation by PD 98059. However, abolishing p38
activation by SB 203580 treatment reduced platelet ad-
hesion by 67  9% at 300 s1 and 56  2% at 1500 s1. In
these conditions, the p38 activity required for platelet
adhesion depends on the 21 collagen receptor. At
higher collagen coverage densities (0.8 g/cm2) support-
ing vWF binding, the inhibition of ERK2 activity by PD
98059 decreased adhesion by 47  6% at 300 s1 and 72 
3% at 1500 s1, whereas p38 inhibition had only a small
effect. The ERK2 activity required for platelet adhesion
was dependent on the interaction of vWF with GPIb. In
conclusion, ERK2 and p38 have complementary effects
in the control of platelet adhesion to collagen in a shear
stress-dependent manner.
The adhesion and aggregation of platelets in response to
vascular injury plays a key role in hemostasis and thrombosis.
Fibrillar collagen is the most abundant thrombogenic molecule
among the macromolecular constituents of the subendothelial
layer. Following exposure to collagen, platelets rapidly adhere,
spread, become active, and then aggregate (1, 2). This interac-
tion of collagen with platelets is both direct and indirect. Under
the high shear stress conditions found in small arteries, the von
Willebrand factor (vWF),1 which binds to newly exposed colla-
gen fibers, is required to capture flowing platelets (3) via the
GPIb-IX-V complex on the platelet surface. This interaction
(vWF-GPIb) cannot support the assembly of a stable platelet
thrombus. Subsequent firm platelet adhesion and activation
are mediated by two major surface receptors for collagen, the
integrin 21 and glycoprotein VI (4–6). The relative contri-
butions of these two receptors to collagen-mediated adhesion
are unclear, and various models have been proposed (7). Ac-
cording to the two-site, two-step model, the major candidate for
involvement in platelet deposition and stabilization on collagen
is 21, with GPVI mediating activation and initiating the
signaling pathway involved in thrombus formation (8). Platelet
activation leads to an increase in the affinity of 21, which in
turn leads to an increase in adhesion stability. Another model
has been proposed in which the absence of functional GPVI
impairs adhesion under static and shear conditions (9, 10). In
this model, GPVI initiates signaling pathways, leading to the
activation of the 21 integrin and of other integrins involved
in firm adhesion at sites of vascular injury (11).
However, the intracellular signaling pathway occurring dur-
ing platelet adhesion and spreading on collagen is poorly un-
derstood. The small GTP-binding proteins Cdc42/Rac and the
effector p21-activated kinases (PAKs) play an important role in
the spreading of platelet lamellipodia over the collagen matrix
(12), and the Cdc42/Rac-dependent activation of PAK involves
cortactin (13). A model of intracellular events during 21-
mediated platelet spreading has been described recently (14).
In this model, the 21 integrin mediates the activation of Src
family kinases and Syk upstream from phospholipase C2 and
the Ca2mobilization required for platelet spreading. A second
pathway may also involve phosphorylation of the tyrosine ki-
nase focal adhesion kinase.
MAP kinases are involved in signaling for cell adhesion and
spreading. They belong to a serine/threonine kinase family that
includes the extracellular signal-regulated kinase (ERK), the
c-Jun N-terminal kinase (JNK), and p38 MAP kinase (15). In
proliferative cells, MAP kinase signaling is essential for normal
cell adhesion and spreading and is regulated by growth factors
and integrins (16). In platelets, ERK2, JNK1, and p38 are
present and activated by various agonists (17–19), but their
role in hemostatic biology and pathology remains unclear.
ERK2 has been reported to be involved in the maintenance of
low thrombin levels, collagen-induced platelet aggregation, and
the activation of IIb3 by vWF ristocetin and thrombin (20–
22). Moreover, P2X1-mediated ERK2 activation amplifies col-
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lagen-induced platelet secretion by enhancing myosin light
chain kinase activation (23). In transgenic mice overexpressing
the P2X1 receptor, injection of a mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase (MEK) in-
hibitor protects against lethal pulmonary thromboembolism
provoked by collagen and epinephrine (24). It also regulates
store-mediated Ca2 entry in platelets (25). In contrast to these
studies implicating ERK2, Watson and co-workers (26) sug-
gested that inhibition of the ERK pathway does not impair the
primary activation of human platelets. GPIb-dependent plate-
let activation has been reported to be dependent on Src kinases
but not MAP kinases (27). The other MAP kinase, p38, is
involved in collagen-induced platelet aggregation (28) and pro-
coagulant activity (29). JNK1 has no known role in platelets.
We investigated the roles of p38 and ERK2 in platelet adhe-
sion and spreading over a collagen matrix in static and blood
flow conditions. We found that both p38 and ERK2 were in-
volved in platelet adhesion. The role of p38 in platelet adhesion
and spreading was independent of blood flow and involved the
21 integrin. In contrast, the role of ERK2 was dependent on
blood flow and vWF-GPIb interaction. We describe here, for the
first time, complementary roles for ERK2 and p38 in platelet
adhesion to collagen under flow conditions.
EXPERIMENTAL PROCEDURES
Materials—Type I acid-soluble calf skin collagen, leupeptin, aproti-
nin, apyrase, and rabbit anti-human vWF were obtained from Sigma.
The MAP kinase inhibitors, PD 98059 and SB 203580, were purchased
from Calbiochem-Novabiochem. Indomethacin was purchased from
Cayman Chemical Co. (Ann Arbor, MI). The anti-p38 MAP kinase,
anti-ERK, and anti-PAK1/2 antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). The antibody against the phosphoryl-
ated form of p38 MAP kinase was purchased from Promega (Madison,
WI) and that against the phosphorylated form of ERK from BIO-
SOURCE International (Camarillo, CA). Anti-Hsp27 and anti-phospho-
Hsp27 (Ser78) polyclonal antibodies were obtained from Upstate Bio-
technology (Lake Placid, NY). The antibody against the phosphorylated
form of PAK1/2 (threonine 423/threonine 402) was obtained from Cell
Signaling Technology (Beverly, MA). Horseradish peroxidase-conju-
gated secondary antibodies were purchased from Jackson ImmunoRe-
search Laboratories (West Grove, PA). Alexa fluor 488-labeled phalloi-
din and Alexa fluor 594-labeled DNase I were obtained from Molecular
Probes (Eugene, OR). Lethal toxin (LT) purified to homogeneity from
Clostridium sordellii (strain IP82) and toxin B from Clostridium diffi-
cile (strain VPI10463) were obtained from Dr M. Popoff (Institut Pas-
teur, Paris). The 6F1 mAb against the 2 integrin was generously
provided by Prof. B. Coller (Mount Sinai Hospital, New York). The mAb
G19H10, which blocks the binding of the vWF to GPIb, was prepared as
described previously (30). Saratin, which blocks the binding of vWF to
collagen, was obtained from Merck (Darmstadt, Germany).
Blood Collection and Platelet Isolation—Venous blood was collected
in 50 M PPACK tubes from healthy donors free of medication for at
least 2 weeks prior to blood collection. Conventional informed consent
was obtained from all donors in accordance with the guidelines of the
French Blood Transfusion Agency. Platelet-rich plasma was obtained
by centrifuging whole blood at 120 g for 15 min at 20 °C, and platelets
were isolated by differential centrifugation. The platelet pellet was
resuspended in 10 mM HEPES, pH 7.4, 140 mM NaCl, 3 mM KCl, 5 mM
NaHCO3, 0.5 mM MgCl2, and 10 mM glucose.
Static Platelet Deposition—Suspended platelets (50 l at 200,000
platelets/l) in the presence of indomethacin (5 M) were plated with SB
203580 (20 M), PD 98059 (20 M), or Me2SO in wells previously coated
with collagen (20 g/ml or 100 g/ml) corresponding to 0.2 g/cm2 or 1
g/cm2) for 1 h at 20 °C. Indomethacin was added to prevent nonspecific
effects of SB 203580 and PD 98059 on cyclooxygenase. Plates were
washed three times in phosphate-buffered saline (PBS). Nonspecific
adhesion was determined in wells precoated with 0.5% bovine serum
albumin in PBS (PBS-BSA). Platelet deposition was quantified by an
acid phosphatase assay as described previously (31).
Flow Experiments and Image Analysis—Whole blood perfusion ex-
periments were performed in a parallel plate perfusion chamber.
Briefly, glass coverslips were coated by overnight incubation at 4 °C
with 500 l of 20 or 100 g/ml collagen, giving coverage densities of 0.04
and 0.8 g/cm2, respectively, allowing platelet adhesion but not throm-
bus formation. Various substances were added to the blood at 37 °C 15
min before perfusion: indomethacin (5 M) in the presence of SB 203580
(20 M), PD 98059 (20 M), or Me2SO. In all experiments, indomethacin
was added to prevent nonspecific effects of SB 203580 and PD 98059 on
cyclooxygenase. Where indicated, antibodies 6F1 (20 g/ml) and
G19H10 (30 g/ml) and saratin (10 g/ml) were incubated with platelet-
rich plasma for 15 min at 37 °C before use in the presence or absence of
a MAP kinase inhibitor. Isolated red blood cells (32) (45% of final
volume) were added just before the start of the 4-min perfusion. Blood
was perfused over the coverslip for 4 min with a syringe pump at shear
rates of 300 or 1500 s1. Adherent platelets were washed in PBS, fixed
with 4% paraformaldehyde in PBS, and permeabilized. They were then
saturated by overnight incubation in PBS-BSA at 4 °C and stained for
30 min with FITC-phalloidin (1/200). They were viewed with an epi-
fluorescence microscope (Nikon, Eclipse 600), and surfaces were ana-
lyzed. For each perfused surface, images from 30 random microscopy
fields were collected. The mean area covered by adherent platelets was
determined and analyzed 2 using NIH Image software (rsb.info.nih.gov/
nih-image/). Platelet adhesion is expressed as relative surface coverage
to facilitate the comparison of different treatments.
Quantification of F-actin/G-actin—Platelet (100,000 platelets/l)
preparations containing indomethacin were incubated with or without
SB 203580 (20 M), PD 98059 (20 M), lethal toxin 82 (LT82) (5 g/ml),
toxin B (7.5 g/ml), or Me2SO as a control before plating on collagen
with a surface density of 0.08 g/cm2. They were incubated for 1 h at
20 °C, fixed with 4% paraformaldehyde, permeabilized, and stained by
incubation for 30 min with TRITC-phalloidin (2 M) or with Alexa fluor
594-labeled DNase I (3 M) to detect F-actin and monomeric G-actin,
respectively (33). Platelets were washed three times, and TRITC-phal-
loidin and Alexa fluor 594 DNase I binding were measured on a plate
reader (Fluoroscan Ascent FL, Labsystems) at appropriate excitation/
emission wavelengths. F-actin and G-actin contents were linearly re-
lated to platelet number.
Immunoblotting—Samples were subjected to immunoblotting as de-
scribed previously (22). Platelets were lysed in SDS denaturing buffer
(100 mM NaCl, 50 mM Tris, 50 mM NaF, 5 mM EDTA, 40 mM -glycer-
ophosphate, 100 M phenylarsine oxide, 1% SDS, 5 g/ml leupeptin, 10
g/ml aprotinin, pH 7.4) and heated at 95 °C for 5 min. Protein concen-
tration was determined by Uptima Kit Micro BCA (Monluc¸on, France).
Proteins were separated by SDS-PAGE according to standard protocols.
The protein bands were transferred to membranes and probed with
primary antibodies. Bound antibodies were visualized by chemilumi-
nescence with appropriate horseradish peroxidase-conjugated second-
ary antibodies.
Statistics—Results are expressed as means  S.E. for at least three
independent experiments. Statistical significance was assessed with
Student’s t test for paired comparisons.
RESULTS
Collagen-induced Platelet Deposition Requires p38 MAP
Kinase Activation—We investigated the role of MAP kinases
p38 and ERK2 in washed platelet deposition on collagen type
I applied at a concentration of 20 or 100 g/ml, corresponding
to 0.2 or 1 g/cm2, in the presence or absence of SB 203580
(20 M) and PD 98059 (20 M). In all conditions, control
platelets or platelets with inhibitors were pretreated with
indomethacin (5 M) to prevent nonspecific effects of the
inhibitors on cyclooxygenase. At a collagen density of 0.2
g/cm2, the inhibitor of MEK (PD 98059) inhibited platelet
deposition by 27  2% (6.6  105 platelets versus 9.0  105
platelets for the indomethacin with Me2SO control; p 
0.001) (Fig. 1A). SB 203580 gave even stronger inhibition, up
to 67  3% (3  105 platelets; p  0.001). In contrast, at
higher collagen coverage density (1 g/cm2), platelet deposi-
tion was not affected whatever the MAP kinase inhibitor
used; deposition levels were similar to those for the indo-
methacin with Me2SO control. Similar results were obtained
with other MEK (U0126: 10 M) and p38 (SB 202190: 10 M)
inhibitors and with lower concentrations of SB203580 (1–5
M) (results not shown). In parallel, we investigated the level
2 A. Mazharian, S. Roger, P. Maurice, E. Berrou, M. R. Popoff, M. F.
Hoylaerts, F. Fauvel-Lafeve, A. Bonnefoy, and M. Bryckaert, personal
communication.
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of phosphorylation of ERK2 (ERK2-P) and p38 (p38-P) re-
quired for activity in the presence and absence of inhibitors
(Fig. 1B and C). ERK2-P was detected only in platelets de-
posited on the higher density of collagen (1 g/cm2) and was
inhibited by PD 98059. p38-P was detected whatever the
density of collagen used (Fig. 1C). As SB 203580 inhibits p38
activity but not p38 phosphorylation, we assessed the level of
phosphorylation of an indirect substrate of p38, the heat-
shock protein Hsp27 (Hsp27-P). As expected, Hsp27-P but
not p38-P was inhibited by SB 203580.
In static adhesion conditions, much of the adhesion observed
was secondary to platelet-platelet interaction through the
IIb3 integrin. We investigated the role of p38 in adhesion
and/or aggregation using the RGDS peptide (1 mM) and inhib-
itors of MAP kinases. Adhesion in the presence or absence of
the RGDS peptide indicated that IIb3 interaction was not
involved at this density of collagen (0.2 g/cm2) and that the
inhibition of adhesion observed with indomethacin (30%) was
because of thromboxane A2, which is involved in platelet
adhesion only (Fig. 2). The addition of SB 203580 in the
presence and absence of the RGDS peptide confirmed that
p38 affected platelet adhesion but not platelet aggregation.
Our results indicate that p38 plays a major role in collagen-
induced platelet adhesion, whereas ERK2 has only a very
small effect.
Collagen-induced Platelet Spreading Requires p38 MAP
Kinase Activation but Not ERK2 Activation—We investigated
the roles of p38 and ERK2 in platelet spreading over a colla-
gen matrix (0.2 g/cm2) under conditions in which MAP ki-
nases have been shown to be involved in platelet adhesion.
Polymerized actin was stained with FITC-phalloidin. As ex-
pected, polymerized actin formed characteristic filipodia and
lamellipodia (Fig. 3A). In the presence of PD 98059 (20 M),
the formation of filipodia and the spreading of lamellae were
systematically observed. In contrast, platelet spreading was
inhibited by SB 203580 (20 M); platelets were round without
lamellipodial extensions. We quantified the surface area of
each platelet labeled with FITC-phalloidin in an attempt to
confirm these results (Fig. 3B). SB 203580 inhibited platelet
spreading by 35  3%, whereas PD 98059 had no inhibitory
effect (4  2%). Similar platelet spreading results were ob-
tained after 1 h in the presence of SB203580 (results not
shown). Thus, p38 is involved in platelet spreading, whereas
ERK2 is not.
The Involvement of p38 Activation in Platelet Spreading Does
Not Depend on Actin Polymerization—Actin-rich filipodial and
lamellipodial protrusions and activation of the small guanosine
triphosphate GTPase Rac1 are required for platelet spreading (13).
FIG. 1. Role of ERK2 and p38 in adhesion of washed platelets
to type I collagen. Platelet suspensions were first incubated with
indomethacin (5 M) for 15 min at 37 °C in the presence of the MAP
kinase inhibitors PD 98059 (20 M), SB 203580 (20 M), or Me2SO for
the controls. They were then added to wells coated with collagen (0.2 or
1 g/cm2) for 1 h at 20 °C. A, platelet deposition was assessed by acid
phosphatase assay. Western blotting was carried out in the presence or
absence of MAP kinase inhibitors with suspended platelets in the first
lane and adherent platelets in the lanes with collagen. B and C, we
probed for phosphorylated and nonphosphorylated forms of ERK2 (B)
and p38 and its indirect substrate Hsp27 (C). Data are expressed as
the mean  S.E. of at least three independent experiments. Data
are statistically significant according to Student’s t-test (**, p  0.01;
***, p  0.001).
FIG. 2. Role of IIb3 integrin in adhesion of washed platelets
to type I collagen. Platelet suspensions were first incubated for 15
min at 37 °C with MAP kinase inhibitors PD 98059 (20 M), SB 203580
(20 M), or Me2SO with or without indomethacin (5 M) in the presence
(hatched bars) or absence of RGDS peptide (1 mM). The samples were
then added to wells coated with collagen (0.2 g/cm2) and incubated for
2 h at 20 °C. Platelet deposition was assessed by acid phosphatase
assay. Data are expressed as the mean  S.E. of at least six independ-
ent experiments. Data are statistically significant according to Stu-
dent’s t-test (***, p  0.001).
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We investigated the role of p38 and ERK2 in actin cytoskeletal
remodeling by determining the F-actin/G-actin ratio, which reflects
F-actin polymerization. The F-actin/G-actin ratio of platelets ad-
hering to collagen had increased by 60 10% after 5 min (Fig. 4A).
In these conditions, SB 203580 and PD 98059 did not affect the
F-actin/G-actin ratio in response to collagen. Thus, p38 is involved
in platelet spreading but not in actin polymerization.
We then used toxin B from C. difficile and LT82 from C. sor-
dellii to determine whether the small G protein Rac required
for platelet spreading was involved in p38 activation. Toxin B
inactivates Rho, Rac, and Cdc42, whereas LT82 inactivates
p21ras, Ra1, Rap, and Rac proteins (34, 35). LT82 (5 g/ml) and
toxin B (7.5 g/ml) decreased the collagen-induced F-actin/G-
actin ratio by 79 and 84%, respectively (Fig. 4B). It also inhib-
ited collagen-induced PAK2 phosphorylation, one of the most
precisely characterized effectors of Rac/Cdc42 involved in la-
mellipodia formation (Fig. 4C). In these conditions, p38 phos-
phorylation was inhibited by 57 and 69%, respectively (Fig.
4D). Our findings suggest that p38 activation is largely depend-
ent on Rac activation. This Rac activation, and possibly the
activation of other small G proteins, induces p38 phosphoryla-
tion and actin polymerization by two different pathways, both
of which are required for spreading.
Involvement of p38 and ERK2 in Platelet Adhesion to Colla-
gen under Blood Flow Conditions—We investigated the roles of
p38 and ERK2 in blood perfusion in conditions of low collagen
coverage density (0.08 and 0.4 g/cm2), allowing platelet adhe-
sion but not thrombus formation. Blood was perfused over
immobilized type I collagen at a low (300 s1) or high (1500 s1)
shear rate to ensure GPIb-dependence. Blood was first treated
with indomethacin to prevent PD 98059 and SB 203580 from
having nonspecific effects on cyclooxygenase and consequently
on thromboxane A2 formation. We compared adhesion at 1500
s1 in the presence and absence of indomethacin. We found
that thromboxane A2 played only a minor role (7%) in blood
flow (results not shown). After 4 min of blood perfusion over
collagen at low coverage density (0.08 g/cm2), the p38 inhib-
itor (SB 203580) decreased collagen-induced platelet adhesion
by 67  9 and 56  2% at 300 and 1500 s1, respectively (Fig.
5). Similar results were obtained with the other p38 inhibitor,
SB 202190 (10 M) (results not shown). In contrast, the MEK
inhibitor had little (8  2%) or no effect (15  8%), regardless
of shear rate (300 and 500 s1). Thus, p38 is also involved in
collagen-induced platelet adhesion under shear conditions. The
inhibition by SB 203580 of platelet deposition in both static and
shear conditions strongly suggests that p38 acts independently
of shear conditions and therefore, probably also independently
of vWF-GPIb interaction.
We investigated the roles of p38 and ERK2 at a higher
density of collagen (0.4 g/cm2) at a shear stress of 300 or 1500
s1. SB 203580 weakly but significantly inhibited (28  9%)
platelet adhesion (Fig. 6) at 1500 s1. Surprisingly, PD 98059
reduced platelet adhesion by 47  6% at 300 s1 and by 72 
3% at 1500 s1. Similar inhibition was obtained with lower
concentrations (2–10 M) of two inhibitors of MEK (U0126 and
PD98059) at 1500 s1 (results not shown). Thus, ERK2 is
involved in platelet adhesion at higher collagen density, and
the involvement of ERK2 seems to depend on shear conditions.
Role of Platelet Receptors 21 and GPIb in MAP Kinase
Activation and Platelet Adhesion—Our results suggest that
activated ERK2 and p38 are involved in platelet adhesion via
different pathways. We therefore investigated the roles of the
collagen receptor, 21 integrin, and GPIb-vWF interaction in
platelet adhesion and MAP kinase activation in high-shear
stress conditions (1500 s1).
We first determined whether vWF was deposited on collagen
at low and higher coverage densities (0.08 or 0.4 g/cm2) after
blood perfusion (4 min). At low collagen density (0.08 g/cm2),
only small amounts of vWF were deposited. Significantly larger
amounts of vWF were deposited at higher density (0.4 g/cm2)
(Fig. 7A). This strongly suggests that the involvement of p38 in
adhesion depends on 21, whereas that of ERK2 depends on
GPIb-vWF interaction and/or 21.
We further investigated the effect of p38 inhibition on plate-
let adhesion to collagen (0.08 g/cm2) in the presence of mAb
6F1 (20 g/ml) to block the integrin 21, mAb G19H10 (30
g/ml) to block the vWF-GPIb interaction, or saratin (10 g/ml)
to block the binding site for the vWF on collagen. We found that
6F1 inhibited platelet adhesion by 87  1%, whereas no signif-
icant inhibition (9  3 and 12  5%) was observed with
G19H10 or saratin (Fig. 7B), as expected given the small
amount of vWF present. In the presence of the p38 inhibitor
alone, platelet adhesion was inhibited by 78  1%, strongly
suggesting that p38 is required for the effect of 21. A similar
level of inhibition was observed in the presence of 6F1 (88 
0.5%). In contrast and as expected, the weak effect on platelet
adhesion of mAb G19H10 (9%) alone was strongly increased by
adding p38 inhibitor (85 0.6%). Similar results were obtained
with saratin in the presence or absence of the p38 inhibitor.
The pathways involving p38 and vWF-GPIb were therefore
different. Thus, the role of p38 in platelet adhesion is depend-
ent on the collagen receptor (21). We investigated the roles
of GPIb and the collagen receptor (21) in the ERK2 acti-
FIG. 3. Role of ERK2 and p38 platelet spreading on type I
collagen. Platelet suspensions were incubated with indomethacin (5
M) in the presence of the MAP kinase inhibitors PD 98059 (20 M), SB
203580 (20 M), or Me2SO for 15 min at 37 °C. They were then added to
wells coated with collagen (0.2 g/cm2) for 2 h at 20 °C (A) and stained
with FITC-phalloidin. B, the surface area was quantified as described
under “Experimental Procedures.” Data are expressed as the mean 
S.E. of four independent experiments. Data are statistically significant
according to Student’s t-test (***, p  0.001).
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vation required for platelet adhesion in conditions of higher
collagen density (0.4 g/cm2) at a shear stress of 1500 s1.
G19H10 and saratin inhibited platelet adhesion by 83  0.8
and 83  1%, respectively, whereas 6F1 gave only weak
inhibition (22  3%) (Fig. 7C). In the presence of the MEK
inhibitor alone, platelet adhesion was inhibited by 71  2%,
suggesting that the effect of ERK2 is largely, if not entirely,
dependent on GPIb-vWF interaction. Moreover, similar lev-
els of inhibition were observed with G19H10 and saratin in
the presence (83  0.8; 87  1%) and absence (85  0.7; 87 
0.8%) of the MEK inhibitor, confirming that the involvement
of ERK2 was totally dependent on vWF-GPIb interaction.
DISCUSSION
This study shows that ERK2 and p38 play different roles in
platelet adhesion over collagen matrix under static and shear
conditions. The involvement of p38 in platelet adhesion and
spreading is independent of shear stress, requires the 21
integrin, and is probably initiated by the GPVI signaling path-
way. Conversely, the involvement of ERK2 in platelet adhesion
is dependent on shear stress and requires vWF-GPIb interac-
tion. We also provide evidence that a small G protein, probably
activated Rac (results not shown), induces p38 phosphorylation
and actin polymerization by two different pathways, both of
which are required for platelet spreading.
In recent years, much progress has been made toward un-
derstanding collagen interactions with specific platelet recep-
tors, but the intracellular signaling involved in platelet adhe-
sion and spreading on collagen-coated surfaces remains poorly
characterized. MAP kinase-signaling molecules activated dur-
ing adhesion and spreading in proliferative cells have been
described extensively (36). In platelets activated by a throm-
boxane A2 analog, p38 activation has been reported to be in-
volved in adhesion to immobilized fibrinogen (37). In this
study, we showed that two MAP kinases, ERK2 and p38, were
activated during adhesion to immobilized collagen in static
conditions and that only p38 was required for adhesion and
spreading. Moreover, p38 acted on platelet adhesion but not on
platelet aggregation. 21 has been reported to be involved in
platelet deposition on collagen-coated surfaces. Only 10% of
GPIa-deficient platelets adhered to type I collagen versus 80%
of control platelets (38). Anti-21 antibody also inhibits plate-
let adhesion or deposition on collagen, whereas anti-GPVI an-
tibody has no effect (39). The lack of involvement of the vWF in
the static adhesion of washed platelets at collagen densities of
0.2 and 1 g/cm2 (results not shown) and the involvement of
p38 only at a collagen density of 0.2 g/cm2 strongly suggest
that different signaling pathways via the collagen receptors
(21 and GPVI) are engaged during platelet deposition at low
and high collagen densities. Platelet spreading on the 21-
specific GFOGER peptide was recently reported to require the
activation of Src kinases and phospholipase C2 (14). We show
here that the role of p38 in adhesion depends largely on 21,
suggesting that platelet spreading via 21 involves p38 activ-
ity. Spreading requires actin polymerization. Several lines of
evidence suggest that the indirect substrate of p38, Hsp27,
controls cytoskeletal reorganization and actin polymerization.
FIG. 4. Activation and roles of ERK2 and p38 in the actin polymerization required for spreading. Platelet suspensions were incubated
with indomethacin (5 M) in the presence of the MAP kinase inhibitors PD 98059 (20 M), SB 203580 (20 M), or Me2SO for 15 min at 37 °C (A)
or with LT 82 (5 g/ml) (hatched) or toxin B (7.5 g/ml) (horizontal stripes) for 2 h at 37 °C (B–D). The platelets were then added to wells coated
with collagen (0.2 g/cm2) for 1 h at 20 °C and were stained with TRITC-phalloidin (F-actin) and DNase I (G-actin). The F-actin/G-actin ratio was
determined, and the data are expressed as the mean  S.E. of four independent experiments. In parallel, we immunoblotted the phosphorylated
forms of PAK1/2 (C) and p38 (D) in the presence or absence of LT 82 and toxin B. Data are expressed as the mean  S.E. of at least three different
experiments. Data are statistically significant according to Student’s t-test (***, p  0.001).
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In smooth muscle cells, the p38 cascade induced by platelet-
derived growth factor controls the actin polymerization re-
quired for lamellipodium formation via the indirect substrate
Hsp27 (33). In platelets, thrombin-induced aggregation leads to
the activation of p38 and MAP kinase-activated protein kinase
and the phosphorylation of Hsp-27, resulting in actin polymer-
ization (40). In our model, the p38 cascade was not involved in
actin polymerization on collagen, suggesting the existence of
two different pathways between actin polymerization and p38
activation, both of which are involved in platelet spreading.
The activation of Rac, a small guanosine triphosphate-binding
protein, and of PAK is required for actin polymerization and
spreading on collagen-coated surfaces (12). Src family kinases
and the phosphatidylinositol 3-kinase are involved in this proc-
ess (12). In proliferative cells, the link between Rac/PAK acti-
vation and p38 activation is unclear. The activation of p38 has
been reported to be dependent on Ras but independent of Rac
(41) and to involve the serine/threonine kinase PAK (42). Rac
activation was observed in this study (results not shown), and
we investigated the relationship between Rac activation and
p38 activation. Clostridial toxin B and lethal toxin 82 inhibited
actin polymerization as reported previously (13). Spreading on
a collagen-coated surface was inhibited in the presence of these
toxins. In these conditions, phosphorylated p38 levels were
very low, demonstrating that p38 phosphorylation is largely
dependent on a small G protein, probably Rac. In platelets, p38
activation and actin polymerization, both of which are required
for spreading, are probably dependent on Rac activation.
We show here, for the first time, that in blood flow conditions
and at low collagen coverage density (0.08 g/cm2), p38 is
involved in adhesion, whereas ERK2 plays only a minor role.
The effect of p38 seemed to be independent of shear stress.
Collagen and the vWF have been reported to activate p38 in
platelet aggregation (19). In our low collagen density condi-
tions, even at shear rates as high as typically encountered in
arterioles (1500 s1), only small amounts of plasma vWF bound
to collagen, strongly suggesting that p38 exerted its effects on
adhesion via the collagen receptors (21 and GPVI). These
results were confirmed by the results for platelet adhesion to
collagen-coated surfaces (0.08 g/cm2 and 1500 s1), which was
fully dependent on the collagen receptor 21 (87%). This ap-
parent discrepancy with published results showing that both
GPIb and 21 contribute to primary adhesion under flow in
these shear stress conditions (43) may be due to the low density
of collagen (0.08 g/cm2), precluding plasma vWF binding,
and/or the low levels of fibrillar collagen at this density of
collagen (0.08 g/cm2). In either case, platelet 21 function is
essential for irreversible platelet attachment, even at high
shear stress (45). Savage et al. (44) reported that 21 inhibi-
tion completely prevented platelet adhesion to acid-soluble col-
lagen but had no effect on binding to native insoluble fibrillar
collagen. We cannot rule out the possible gradual production of
fibrillar collagen from acid-soluble collagen, leading to the ac-
tivation of GPVI, enhancing adhesion by inside-out signaling to
21. Such differences in collagen structure have been re-
ported to be directly related to differences in vWF content (45).
In pathological conditions such as atherogenesis, in vivo stud-
ies have shown that collagen fibers may be degraded because of
an increase in the matrix metalloproteinase activity of infil-
trating macrophages and activated smooth muscle cells (46).
FIG. 5. Roles of ERK2 and p38 in
platelet adhesion to collagen (0.08 g/
cm2) under flow conditions. The blood
cell suspension was incubated with indo-
methacin (5 M) in the presence or ab-
sence of PD 98059 (20 M), SB 203580 (20
M), or Me2SO for 15 min at 37 °C (A and
B). Blood was perfused for 4 min at a
shear rate of 300 or 1500 s1 over immo-
bilized collagen (0.08 g/cm2). Adherent
platelets were labeled with FITC-phalloi-
din. Data are expressed as the mean 
S.E. of four independent experiments.
Data are statistically significant accord-
ing to Student’s t-test (**, p  0.01;
***, p  0.001).
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These findings suggest that 21 plays a major role in these
conditions.
At a collagen density (0.4 g/cm2) allowing adhesion but not
thrombus formation (44), ERK2 was involved in platelet adhe-
sion, and its role seemed to depend on shear stress. In static
conditions, ERK2 had no effect on platelet adhesion, whereas
at 1500 s1, adhesion was inhibited by 75% in the presence of
the MEK inhibitor. This apparent discrepancy between static
adhesion and blood flow could be explained by the presence of
the vWF, involved in ERK2 activation, in blood flow. At higher
collagen densities, the vWF was readily detected bound to the
collagen matrix, and adhesion depended largely (83%) on vWF-
GPIb interaction and to a lesser extent (22%) on collagen re-
ceptors (such as 21), strongly suggesting that much of the
effect of ERK2 (71%) on adhesion was dependent on the vWF.
This hypothesis was confirmed by the inhibition of adhesion
(22%) observed in the presence of 6F1 and its increase to 79%
after the addition of the MEK inhibitor. There are two possible
reasons why the MEK inhibitor alone inhibited platelet adhe-
sion (71%) to a lesser extent than mAb G19H10 (85%) or sara-
tin (87%). The vWF-GPIb interaction involved in platelet ad-
hesion may depend on at least two different pathways, with the
major pathway dependent on ERK2 activation and the second
independent of ERK2 activation. Alternatively, ERK2 activity
may not be totally inhibited by PD 98059. Moreover, whereas
adhesion at 300 s1 was largely dependent on 21 (62%) and
to a lesser extent on GPIb-vWF interaction (39%; results not
shown), the inhibition of adhesion by PD 98059 was weaker
and depended on GPIb-vWF interaction. This strongly suggests
that ERK2 plays a major role in platelet adhesion to the arte-
rial subendothelium. Our results show, for the first time, that
the role of ERK2 in human platelet adhesion under shear
conditions is largely dependent on the vWF. In previous stud-
ies, the vWF has been reported to activate IIb3 and conse-
quently to induce platelet aggregation via ERK2 activation
(20). In our collagen model, using two inhibitors of MEK
(PD98059 and U0126), vWF/GPIb interaction induced platelet
adhesion via ERK2, showing that ERK2 plays a major role in
adhesion and thrombus formation. However, in mouse plate-
lets, Watson and co-workers (27) showed that ERK2 was not
involved in adhesion to collagen in blood flow conditions. Dif-
ferences between these models (mouse versus human platelets)
may account for the divergent findings concerning the role of
ERK2 at high shear rates. Our data are consistent with the
involvement of the ERK2 pathway in platelet aggregation on
collagen under flow conditions in transgenic mice via the plate-
let P2X1 ion channel (24) and suggest that, in human platelets,
the P2X1 pathway and the vWF bound to collagen are involved
in platelet activation and the development of thrombosis via
the MAP kinase ERK2. Finally, the role of ERK2 at high shear
rate (1500 s1) dependent on vWF-GPIb interaction and the
role of ERK2 dependent on the P2X1 ion channel in thrombo-
embolism (24) are two different and complementary pathways,
both of which contribute to platelet thrombus formation.
In conclusion, we report here the differential involvement of
ERK2 and p38 in adhesion during the perfusion of whole blood
over a collagen matrix (Fig. 8). In models of vessel wall damage
resembling thrombosis, small numbers of collagen fibers are
exposed and vWF binding cannot take place. In these condi-
tions, platelets adhere directly via collagen receptors (21/
FIG. 6. Roles of ERK2 and p38 in
platelet adhesion to collagen (0.4 g/
cm2) under flow conditions. The blood
cell suspension was first incubated with
indomethacin (5 M) in the presence or
absence of PD 98059 (20 M), SB 203580
(20 M), or Me2SO for 15 min at 37 °C (A
and B). Blood was perfused for 4 min at a
shear rate of 300 or 1500 s1 over immo-
bilized collagen (0.4 g/cm2). Adherent
platelets were labeled with TRITC-phal-
loidin. Data are expressed as the mean 
S.E. of four independent experiments.
Data are statistically significant accord-
ing to Student’s t-test (**, p  0.01;
***, p  0.001).
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GPVI), and this adhesion is dependent on p38. In another type
of vessel wall damage, at high shear rates (as in arteries)
collagen fibers are exposed and vWF binds. In this model,
platelets initially interact via glycoprotein Ib-V-IX and vWF
bound to collagen. This process is dependent on ERK2 activa-
tion followed by irreversible adhesion to the collagen receptor.
Acknowledgments—We thank B. Coller for generously providing
mAb 6F1 against 2 integrin. We also thank C. Amant for technical
assistance and A. Bruel, who is in charge of the video microscopy
platform (IFR 105, Hoˆpital Saint Louis, Paris).
REFERENCES
1. Rauterberg, J., Jaeger, E., and Althaus, M. (1993) Curr. Top. Pathol. 163–192
2. Baumgartner, H. R., Tschopp, T. B., and Weiss, H. J. (1977) Thromb. Haemo-
stasis 37, 17–28
3. Savage, B., Saldivar, E., and Ruggeri, Z. M. (1996) Cell 84, 289–297
4. Farndale, R.W., Sixma, J. J., Barnes, M. J., and De Groot, P. G. (2004) J.
Thromb. Haemostasis 2, 561–573
5. Watson, S. P., and Gibbins, J. (1998) Immunol. Today 19, 260–264
6. Siljander, P. R-M., and Farndale, R.W. (2002) in Platelets in Thrombotic and
Non-thrombotic Disorders: Pathophysiology, Pharmacology, and Therapeu-
tics (Gresele, P., Page, C. P., Fuster, V., and Vermylen, J., eds) pp. 158–178,
Cambridge University Press, Cambridge, UK
7. Saelman, E. U., Nieuwenhuis, H. K., Hese, K. M., De Groot, P. G., Heijmen,
H. F., Sage, E. H., Williams, S., McKeown, L., Gralnick, H. R., and Sixma,
J. J. (1994) Blood 83, 1244–1250
8. Moroi, M., Jung, S. M., Shinmyozu, K., Tomiyama, Y., Ordinas, A., and
Diaz-Ricart, M. (1996) Blood 88, 2081–2092
9. Nieswandt, B., Brakebusch, C., Bergmeier, W., Schulte, V., Bouvard, D.,
Mokhtari-Nejad, R., Lindhout, T., Heemskerk, J. W., Zirngibl, H., and
Fassler, R. (2001) EMBO J. 20, 2120–2130
10. Goto, S., Tamura, N., Handa, S., Arai, M., Kodama, K., and Takayama, H.
(2002) Circulation 106, 266–272
11. Nieswandt, S., and Watson, S. P. (2003) Blood 102, 449–461
12. Suzuki-Inoue, K., Yatomi, Y., Asazuma, N., Kainoh, M., Tanaka, T., Satoh, K.,
and Ozaki, Y. (2001) Blood 98, 3708–3716
13. Vidal, C., Geny, B., Melle, J., Jandrot-Perrus, M., and Fontenay-Roupie, M.
FIG. 7. Role of collagen receptor 21 and GPIb-vWF interac-
tion in platelet adhesion and MAP kinase activation. A, platelet-
poor plasma with red cells was perfused at a shear rate of 1500 s1 over
immobilized collagen (0.08 and 0.4 g/cm2). The vWF was visualized by
immunofluorescence microscopy. B and C, platelet-rich plasma was
incubated with mAbs 6F1 (20 g/ml) or G19H10 (30 g/ml) or saratin
(10 g/ml) and indomethacin (5 M) in the presence or absence of SB
203580 (20 M) and PD 98059 (20 M) or Me2SO for 15 min at 37 °C
before the addition of red cells. The blood was then perfused at a shear
rate of 1500 s1 for 4 min over immobilized collagen (0.08 g/cm2 (B)
and 0.4 g/cm2 (C)). Adherent platelets were labeled with FITC-phal-
loidin. Data are expressed as the mean  S.E. of four independent
experiments.
FIG. 8. Complementary roles of ERK2 and p38 in platelet ad-
hesion. First model (A), in small vessel wall damage, a low level of
collagen fibers does not support vWF binding. Platelets adhere directly
via collagen receptor 21, and this adhesion is dependent on p38.
Second model (B), in vessel injury (high shear rates, as in arteries),
which allow the binding of the vWF to collagen, platelets initially
interact via glycoprotein Ib-V-IX with the von Willebrand factor bound
to collagen; this process is dependent on ERK2 activation, after which
irreversible binding to collagen receptors occurs.
MAP Kinases in Platelet Adhesion 26009
(2002) Blood 100, 4462–4469
14. Inoue, O., Suzuki-Inoue, K., Dean, W. L., Frampton, J., and Watson, S. P.
(2003) J. Cell Biol. 160, 769–780
15. Rossomando, A. J., Payne, D. M., Weber, M. J., and Sturgill, T. W. (1989) Proc.
Natl. Acad. Sci. U. S. A. 86, 6940–6943
16. Cobb, M. H., Boulton, T. G., and Robbins, D. J. (1991) Cell Regul. 2, 965–978
17. Nadal, F., Levy-Toledano, S., Grelac, F., Caen, J. P., Rosa, J.-P., and Bryck-
aert, M. (1997) J. Biol. Chem. 272, 22381–22384
18. Bugaud, F., Nadal-Wollbold, F., Levy-Toledano, S., Rosa, J.-P., and Bryckaert,
M. (1999) Blood 94, 3800–3805
19. Canobbio, I., Reineri, S., Sinigaglia, F., Balduini, C., and Torti, M. (2004)
Thromb. Haemostasis 91, 102–110
20. Li, Z., Xi, D., and Du, X. (2001) J. Biol. Chem. 276, 42226–42232
21. Li, Z., Xi, D., Gu, M., Feil, R., Ye, R. D., Eigenthaler, M., Hofmann, F., and Du,
X. (2003) Cell 112, 77–86
22. Roger, S., Pawlowski, M., Habib, A., Jandrot-Perrus, M., Rosa, J.-P., and
Bryckaert, M. (2004) FEBS Lett. 556, 227–235
23. Toth-Zsamboki, E., Oury, C., Conelessen, H., De Vos, R., Vermylen, J., and
Hoylaerts, M. F. (2003) J. Biol. Chem. 278, 46661–46667
24. Oury, C., Kuijpers, M., Toth-Zsamboki, E., Bonnefoy, A., Danloy, S., Vreys, I.,
Feijge, A. H., De Vos, R., Vermylen, J., Heemskerk, J. W., and Hoylaerts, M.
(2003) Blood 101, 3969–3976
25. Rosado, J. A., and Sage S. O. (2001) J. Biol. Chem. 276, 15659–15665
26. Borsch-Haubold, A. G., Kramer, R. M., and Watson, S. P. (1996) Biochem. J.
318, 207–212
27. Marshall, S. J., Senis, Y. A., Auger, J. M., Feil, R., Hofmann, F., Salmon, G.,
Peterson, T., Burslem, F., and Watson, S. P. (2004) Blood 103, 2601–2609
28. Saklatvala, J., Rawlinson, L., Waller, R. J., Sarsfield, S., Lee, J. C., Morton,
L. F., Barnes, M. J., and Farndale, R. W. (1996) J. Biol. Chem. 271,
6586–6589
29. Siljander, P., Farndale, R. W., Feijge, M. A., Comfurius, P., Kos, S., Bevers,
E. M., and Heemskerk, J. W. (2001) Arterioscler. Thromb. Vasc. Biol. 21,
618–627
30. Theilmeier, G., Lenaerts, T., Remacle, C., Collen, D., Vermylen, J., and Hoy-
laerts, M. F. (1999) Blood 94, 2725–2734
31. Lewis, J. M., Cheresh, D. A., and Schwartz, M. A. (1996) J. Cell Biol. 134,
1323–1332
32. Bonnefoy, A., Yamamoto, H., Thys, C., Kito, M., Vermylen, J., and Hoylaerts,
M. F. (2003) Blood 101, 1375–1383
33. Pichon, S., Bryckaert, M., and Berrou, E. (2004) J. Cell Sci. 117, 2569–2577
34. Popoff, M. R., Chaves-Olarte, E., Lemichez, E., von Eichel-Streiber, C., The-
lestam, M., Chardin, P., Cussac, D., Antonny, B., Chavrier, P., Flatau, G.,
Giry, M., de Gunzburg, J., and Boquet, P. (1996) J. Biol. Chem. 271,
10217–10224
35. Richard, J.-F., Petit, L., Gibert, M., Marvaud, J. C., Bouchaud, C., and Popoff,
M. R. (1999) Int. Microbiol. 2, 185–194
36. Chen, Q., Kinch, M. S., Lin, T. H., Burridge, K., and Juliano, R. L. (1994)
J. Biol. Chem. 269, 26602–26609
37. Minuz, P., Gaino, S., Zuliani, V., Tommasoli, R., Benati, D., Ortolani, R.,
Zancanaro, C., Berton, G., and Santonastaso, C. L. (2002) Thromb. Haemo-
stasis 87, 888–898
38. Kehrel, B., Balleisen, L., Kokott, R., Mesters, R., Stenzinger, W., Clemetson,
K. J., and Van de Loo, J. (1988) Blood 71, 1074–1078
39. Nakamura, T., Kambayashi, J., Okuma, M., and Tandon, N. N. (1999) J. Biol.
Chem. 274, 11897–11903
40. Zhu, Y., O’Neill, S., Saklatvala, J., Tassi, L., and Mendelsohn, M. E. (1994)
Blood 84, 3715–3723
41. Matsumoto, T., Yokote, K., Tamura, K., Takemoto, K., Ueno, H., Saito, Y., and
Mori, S. J. (1999) J. Biol. Chem. 274, 13954–13960
42. Dechert, M. A., Holder, J. M., and Gerthoffer, W. T. (2001) Am. J. Physiol. 281,
C123–C132
43. Siljander, P. R.-M., Munnix, I. C. A., Smethurst, P. A., Deckmyn, H., Lindhout,
T., Ouwehand, W. H., Farndale, R. W., and Heemskerk, J. W. M. (2004)
Blood 103, 1333–1341
44. Savage, B., Ginsberg, M. H., and Ruggeri, Z. M. (1999) Blood 94, 2704–2715
45. Bernado, A., Bergeron, A. L., Sun, C. W., Guchhait, P., Cruz, M. A., Lopez,
J. A., and Dong, J. F. (2004) J. Thromb. Haemost. 2, 660–669
46. Raines, E. W., Koyama, H., and Carragher, N. O. (2000) Ann. N. Y. Acad. Sci.
902, 39–51
MAP Kinases in Platelet Adhesion26010
